Matthew P Deek1, Sinae Kim2, Ning Yue1, Rekha Baby1, Inaya Ahmed1, Wei Zou1, John Langenfeld3, Joseph Aisner4, Salma K Jabbour1. 1. Rutgers Cancer Institute of New Jersey, Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. 2. School of Public Health, Biometrics Division, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 3. Rutgers Cancer Institute of New Jersey, Division of Cardiothoracic Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. 4. Rutgers Cancer Institute of New Jersey, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Abstract
BACKGROUND: To investigate the impact of advances in image-guided radiotherapy (IGRT) on the outcomes of patients with non-small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT). METHODS: We retrospectively reviewed 91 patients with NSCLC treated with definitive CRT using image guidance with daily orthogonal kilovoltage (kV) imaging compared to standard weekly megavoltage (MV) portal verifications. Kaplan-Meier curves for overall survival and locoregional failure were computed and stratified by image guidance techniques. Log-rank tests were used to compare strata. Cox Proportional Hazards models were used to identify risk factors for worse mortality and locoregional control. RESULTS: Fifty-four percent (n=49) of patients received weekly MV portal imaging, while 46% (n=42) underwent IGRT using daily orthogonal kV imaging. kV IGRT was associated with longer median survival (36.4 months) compared to MV imaging (14.9 months; P=0.01). kV imaging was also marginally associated with lower risk of locoregional failure. Median time to local progression in patients imaged with kV was 21.4 months compared to 10.9 months (P=0.065) for those treated with MV portal imaging. CONCLUSIONS: Daily kV imaging appears to be marginally associated with better survival and disease control when compared to MV imaging. Given the small study size and the numerable factors tested, these finding require additional confirmation.
BACKGROUND: To investigate the impact of advances in image-guided radiotherapy (IGRT) on the outcomes of patients with non-small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT). METHODS: We retrospectively reviewed 91 patients with NSCLC treated with definitive CRT using image guidance with daily orthogonal kilovoltage (kV) imaging compared to standard weekly megavoltage (MV) portal verifications. Kaplan-Meier curves for overall survival and locoregional failure were computed and stratified by image guidance techniques. Log-rank tests were used to compare strata. Cox Proportional Hazards models were used to identify risk factors for worse mortality and locoregional control. RESULTS: Fifty-four percent (n=49) of patients received weekly MV portal imaging, while 46% (n=42) underwent IGRT using daily orthogonal kV imaging. kV IGRT was associated with longer median survival (36.4 months) compared to MV imaging (14.9 months; P=0.01). kV imaging was also marginally associated with lower risk of locoregional failure. Median time to local progression in patients imaged with kV was 21.4 months compared to 10.9 months (P=0.065) for those treated with MV portal imaging. CONCLUSIONS: Daily kV imaging appears to be marginally associated with better survival and disease control when compared to MV imaging. Given the small study size and the numerable factors tested, these finding require additional confirmation.
Entities:
Keywords:
Image guidance; chemoradiation therapy (CRT); lung cancer
Authors: S Gill; J Thomas; C Fox; T Kron; A Thompson; S Chander; S Williams; K H Tai; G Duchesne; F Foroudi Journal: Br J Radiol Date: 2011-10-05 Impact factor: 3.039
Authors: Eva E Schaake; Maddalena M G Rossi; Wieneke A Buikhuisen; Jacobus A Burgers; Adrianus A J Smit; José S A Belderbos; Jan-Jakob Sonke Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-18 Impact factor: 7.038
Authors: J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey Journal: J Clin Oncol Date: 1986-11 Impact factor: 44.544
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Dario Consonni; Mariaelena Pierobon; Mitchell H Gail; Maurizia Rubagotti; Melissa Rotunno; Alisa Goldstein; Lynn Goldin; Jay Lubin; Sholom Wacholder; Neil E Caporaso; Pier Alberto Bertazzi; Margaret A Tucker; Angela C Pesatori; Maria Teresa Landi Journal: J Natl Cancer Inst Date: 2015-03-23 Impact factor: 13.506
Authors: Vivien W Chen; Bernardo A Ruiz; Mei-Chin Hsieh; Xiao-Cheng Wu; Lynn A G Ries; Denise R Lewis Journal: Cancer Date: 2014-12-01 Impact factor: 6.860